Fungal biomarkers: an update

17:15 • 1557 • Evaluation of <em>Aspergillus </em>galactomannan testing from lower respiratory tract samples for the detection of <em>Aspergillus </em>species > L. Lisa FRIELINGHAUS (Hamburg) 17:20 • 1652 • The significance of combination detection of <em>Aspergillus</em> antigen and antibody lateral flow assay for invasive pulmonary aspergillosis diagnosis > W. Wang RUIZHONG (Shanghai) 17:25 • 1667 • Diagnostic performance of real-time PCR assay on blood for invasive aspergillosis and mucormycosis > H. Hyeonji SEO (Seoul) 17:30 • 1656 • The significance of combination detection of <em>Candida </em>mannan and antibody lateral flow assay for invasive candidiasis diagnosis > X. Xi LI (Zhejiang) 17:35 • 3655 • Usefulness of galactomannan (GM) detection in tracheal/bronchial aspirates of intubated critical COVID-19 adult patients > M. M.Teresa MARTIN-GOMEZ (Barcelona) 17:40 • 1654 • Evaluation of a novel diagnostic method for fungal infection: (1,3)-ß-D-glucan chemiluminescence immunoassay > L. Lizhong HAN (Shanghai) 17:45 • 3545 • Diagnostic performance of the novel Fungitell STAT assay in comparison to the classical Fungitell assay and the Fujifilm Wako β-glucan test in patients with invasive fungal disease > J. Jürgen HELD (Erlangen) 17:50 • 3288 • Biomarkers for the diagnosis of invasive candidiasis in immunocompetent and immunocompromised patients > M. Maria Soledad CUETARA GARCIA (Leganés) 17:55 • 3467 • Smartphone automatic reading of the CrAg lateral flow assay using an AI algorithm can provide quantitative results > A. Ana ALASTRUEY-IZQUIERDO (Madrid) 18:00 • 3526 • Rapid, non-invasive detection of <em>Toxoplasma gondii </em>and <em>Pneumocystis jirovecii</em> in immunocompromised patients using a plasma-based microbial cell-free DNA sequencing test > M. Matthew SMOLLIN (Atlanta) 18:05 • INT86 • Q&A/Discussion